DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service

Food and Drug Administration
Rockville MD 20857

NDA 20-864 S-004, S-005, S-007
NDA 20-865 S-005, S-006, S-007

Merck & Co., Inc.
Attn: Charlene G. Sanders, M.D.
Sumneytown Pike
P.O. Box 4, BLA-20
West Point, PA 19486-0004

Dear Dr. Sanders:

Please refer to the following supplemental new drug applications submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Maxalt® (rizatriptan) Tablets, and Maxalt MLT® (rizatriptan) Orally Disintegrating Tablets.

NDA 20-864 Maxalt®	NDA 20-865 Maxalt MLT®	Letter Date	Receipt Date
S-004	S-005	November 11, 1999	November 12, 1999
S-005	S-006	March 10, 2000	March 13, 2000
S-007	S-007	November 2, 2000	November 3, 2000

We also refer to your amendments dated April 27, July 5, October 25, 2000 submitted to N20-864/S-005 & N20-865/S-006 and to your amendment dated November 7, 2000, submitted to all of these supplemental applications. Finally, reference is also made to your amendment dated November 29, 2000 submitted to N20-864/S-007 & N20-865/S-007.

NDA 20-864/S-004
NDA 20-865/S-005

These "Changes Being Effected" supplemental new drug applications provide for revisions to the WARNINGS, PRECAUTIONS, and ADVERSE REACTIONS sections of the label, based on post-marketing experience in patients with risk factors predictive of CAD, myocardial ischemia or infarction, cerebrovascular accident, and dysgeusia. Additionally, the Patient Package Insert (PPI) has been updated to reflect the changes to the package insert.

NDA 20-864/S-005
NDA 20-865/S-006

These supplemental new drug applications provide for 1) labeling changes regarding the relationship of menses and migraine attacks, and 2) your response to a Phase IV commitment in which you agreed to conduct ICH pre- and post-natal developmental toxicity study in rats using doses that produce adequate evidence of maternal toxicity.

NDA 20-864/S-007
NDA 20-865/S-007

These “Changes Being Affected” supplemental new drug applications provide for a revision in the ADVERSE REACTIONS:Post-Marketing Experience section of the package insert to add the following reaction: “Skin and Skin Appendage: Toxic Epidermal Necrolysis (TEN)”

We have completed the review of these supplemental applications, as amended, and have concluded that adequate information has been presented to demonstrate that the drug products are safe and effective for use as recommended in the agreed upon enclosed labeling text. Accordingly, these supplemental applications are approved effective on the date of this letter.

The final printed labeling (FPL) must be identical to the enclosed labeling (text for the package insert, text for the patient package insert).

Please submit 20 paper copies of the FPL as soon as it is available, in no case more than 30 days after it is printed to each application. Please individually mount ten of the copies on heavy-weight paper or similar material. Alternatively, you may submit the FPL electronically according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format - NDAs* (January 1999). For administrative purposes, these submissions should be designated "FPL for approved supplement NDA xx-xxx/S-yyy, S-zzz." Approval of these submissions by FDA is not required before the labeling is used.

If a letter communicating important information about this drug product (i.e., a "Dear Health Care Practitioner" letter) is issued to physicians and others responsible for patient care, we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HF-2

FDA
5600 Fishers Lane
Rockville, MD 20857

Phase IV Commitment:

We also note that your supplemental applications dated March 10, 2000 (NDA 20-864 S-005; NDA 20-865 S-006), provide results from your post marketing commitment to "do an ICH pre- and post-natal developmental toxicity study in rats using doses that produce adequate evidence of maternal toxicity."

We have completed the review of your post marketing data and conclude that the above commitment has been fulfilled.

This completes all of your post marketing commitments for this application.

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, call Robbin Nighswander, R.Ph., Regulatory Management Officer, at (301) 594-5531.

Sincerely,

Russell Katz, M.D.
Director
Division of Neuropharmacological
Drug Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

Attachment